TransCode Therapeutics, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 22 May 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Debt obligation accelerated (8-K Item 2.04)
The company reported a triggering event that accelerates or increases a debt obligation in a Form 8-K (Item 2.04) filed on 01 Oct 2026, for example lenders becoming able to demand early repayment.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 31 Mar 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →TransCode Therapeutics, Inc. — Overview & Financial Snapshot
TransCode Therapeutics, Inc. (NasdaqCM: RNAZ) is a Healthcare company, ranked #3,459 of 6,774 companies globally and #1,490 of 4,000 in United States on PositoAI, with a Positivity Score of 20,547. Its market capitalisation is ₹274.08 Cr ($29.04M), P/E ratio is -0.0 and P/B ratio is 0.21. It currently has 1 active red flag (PosiRed) and 2 yellow flags (PosiYellow, 10/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →